Andira Pharmaceuticals Achieves Remarkable Breast Cancer Tumor Regression with Lead Oncology Candidate XOXO4
Andira’s Founder and CEO, Dr. Dana Lambert, revealed, “The Company has achieved extraordinary validation of the efficacy of our lead breast cancer formula, XOXO4, at the University of British Columbia.” The groundbreaking research results demonstrate successful regression of human breast cancer tumors following topical treatment with XOXO4, a cannabinoid formula, in a particular model of breast cancer.
- Andira’s Founder and CEO, Dr. Dana Lambert, revealed, “The Company has achieved extraordinary validation of the efficacy of our lead breast cancer formula, XOXO4, at the University of British Columbia.” The groundbreaking research results demonstrate successful regression of human breast cancer tumors following topical treatment with XOXO4, a cannabinoid formula, in a particular model of breast cancer.
- North American women have a 1 in 8 chance, or 12.9 percent lifetime risk, of being diagnosed with breast cancer.
- The US-based National Breast Cancer Center reports in 2020 that 685,000 people died from breast cancer worldwide, more than one person per minute.
- The Company’s lead oncology candidate, XOXO4, is a patent-pending treatment being developed for estrogen receptor-positive (ER+) breast cancer, the most common form of the disease.